Prostate Cancer Partnering 2007-2012

The Prostate Cancer Partnering 2007-2012 provides understanding and access to the prostate cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of prostate cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors prostate cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.

This data driven report contains over 160 links to online copies of actual prostate cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The initial chapters of this report provide an orientation of prostate cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in prostate cancer partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading prostate cancer deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of prostate cancer partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract
document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of prostate cancer technologies and products.

Report scope

Prostate Cancer Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to prostate cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in prostate cancer dealmaking in the biopharma industry since 2007
Access to summary headline, upfront, milestone and royalty data
Access to over 160 prostate cancer contract documents
The leading prostate cancer deals by value since 2007
In Prostate Cancer Partnering 2007-2012, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Prostate Cancer Partnering 2007-2012 provides the reader with the following key benefits:

In-depth understanding of prostate cancer deal trends since 2007
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 160 actual prostate cancer deals entered into by the worlds biopharma companies since 2007
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies SHOW LESS READ MORE >

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in prostate cancer partnering

2.1. Introduction
2.2. Prostate cancer partnering over the years
2.3. Bigpharma prostate cancer dealmaking activity
2.4. Prostate cancer partnering by deal type
2.5. Prostate cancer partnering industry sector
2.6. Prostate cancer partnering by stage of development
2.7. Prostate cancer partnering by technology type
2.8. Disclosed financial deal terms for prostate cancer
2.8.1 Prostate cancer headline values
2.8.2 Prostate cancer upfront payments
2.8.3 Prostate cancer milestone payments
2.8.4 Prostate cancer royalty rates
Chapter 3 - Leading prostate cancer deals

3.1. Introduction
3.2. Top prostate cancer deals by value
3.3. Top prostate cancer deals involving bigpharma
Chapter 4 - Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendices

Appendix 1 - Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form - Reports
Table of figures

Figure 1: Prostate cancer partnering since 2007
Figure 2: Bigpharma - top 50 - prostate cancer deals 2007 to 2011
Figure 3: Bigpharma prostate cancer deal frequency - 2007 to 2011
Figure 4: Prostate cancer partnering by deal type since 2007
Figure 5: Prostate cancer partnering by industry sector since 2007
Figure 6: Prostate cancer partnering by stage of development since 2007
Figure 7: Prostate cancer partnering by technology type since 2007
Figure 8: Prostate cancer deals with a headline value
Figure 9: Prostate cancer deals with upfront payment values
Figure 10: Prostate cancer deals with milestone payments
Figure 11: Prostate cancer deals with royalty rates, %
Figure 12: Top prostate cancer deals by value since 2007
Figure 13: Top prostate cancer deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

The Prostate Cancer Partnering 2007-2012 report provides understanding and access to the prostate cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in prostate cancer partnering deals
Top prostate cancer deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type